Abramson Cancer Center at Penn Medicine
Jennifer Zhang
This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers. No randomization or changes to standard of care treatment will occur as part of the study.
Breast Cancer
Are positive breast cancer
HER2-negative Breast Cancer
TNBC - Triple-Negative Breast Cancer
Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 300 participants |
| Official Title : | Role of the Immune Environment in Response to Therapy in Breast Cancer |
| Actual Study Start Date : | 2022-10-03 |
| Estimated Primary Completion Date : | 2032-12-31 |
| Estimated Study Completion Date : | 2032-12-31 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | FEMALE |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Abramson Cancer Center
Philadelphia, Pennsylvania, United States, 19104